Pixclara (floretyrosine f-18)

Where it stands

Pixclara (floretyrosine F-18), from Telix, was approved by the US FDA on 2026-09-11 under NDA 218592. The FDA announced it as a new medicine. The dosage form in the records is a solution.

The records do not state the indication or the therapeutic area, so this analysis cannot say which patients or clinical uses the approval covers. The 'F-18' in the name indicates a fluorine-18 radiolabel, which is typical of radiopharmaceuticals, but the records do not confirm the product's class or use. The approved label should be checked before drawing any clinical or commercial conclusion.

Regulatory pathway and designations

The records show a US New Drug Application (NDA218592) with two designations: New molecular entity and Priority review. New molecular entity means the active moiety had not previously been approved by the FDA. Priority review is an FDA designation that targets a shorter review clock than standard review, generally for products that may offer a significant improvement in treating, diagnosing or preventing a serious condition.

The records give only the approval date, not the submission date, the PDUFA goal date or the review timeline, so they do not show how the actual review compared with the target. No CHMP opinion date is listed. This is a US record, and nothing in it indicates an EU filing or status.

Safety and pharmacovigilance

The records contain no safety information, such as labeled warnings, contraindications, risk management requirements or post-marketing commitments, so none can be assessed here.

What to watch

The records list no future milestones. The first step for professional readers is to obtain the FDA approval documentation and label to confirm the indication, the approved population and any post-marketing requirements.

Whether Telix pursues filings in other regions is not in the records, so no view on ex-US plans is given. Any regional follow-up would have to be confirmed from company or agency communications.